- Home
- NVOS vs BCDA Comparison
NVOS vs BCDA Comparison
Compare NVOS & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVOS
- BCDA
- Stock Information
- Founded
- NVOS 2000
- BCDA N/A
- Country
- NVOS United States
- BCDA United States
- Employees
- NVOS N/A
- BCDA N/A
- Industry
- NVOS Assisted Living Services
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- NVOS Health Care
- BCDA Health Care
- Exchange
- NVOS Nasdaq
- BCDA Nasdaq
- Market Cap
- NVOS 5.6M
- BCDA 7.9M
- IPO Year
- NVOS 2017
- BCDA N/A
- Fundamental
- Price
- NVOS $0.23
- BCDA $2.60
- Analyst Decision
- NVOS
- BCDA Strong Buy
- Analyst Count
- NVOS 0
- BCDA 1
- Target Price
- NVOS N/A
- BCDA $25.00
- AVG Volume (30 Days)
- NVOS 326.8K
- BCDA 74.1K
- Earning Date
- NVOS 12-12-2024
- BCDA 11-06-2024
- Dividend Yield
- NVOS N/A
- BCDA N/A
- EPS Growth
- NVOS N/A
- BCDA N/A
- EPS
- NVOS N/A
- BCDA N/A
- Revenue
- NVOS $13,516,958.00
- BCDA $428,000.00
- Revenue This Year
- NVOS N/A
- BCDA $6.92
- Revenue Next Year
- NVOS N/A
- BCDA N/A
- P/E Ratio
- NVOS N/A
- BCDA N/A
- Revenue Growth
- NVOS 1102.98
- BCDA 0.71
- 52 Week Low
- NVOS $0.20
- BCDA $1.96
- 52 Week High
- NVOS $3.45
- BCDA $23.25
- Technical
- Relative Strength Index (RSI)
- NVOS 38.13
- BCDA 46.60
- Support Level
- NVOS $0.20
- BCDA $2.39
- Resistance Level
- NVOS $0.31
- BCDA $2.84
- Average True Range (ATR)
- NVOS 0.03
- BCDA 0.17
- MACD
- NVOS 0.00
- BCDA -0.00
- Stochastic Oscillator
- NVOS 27.18
- BCDA 41.18
About NVOS Novo Integrated Sciences Inc.
Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services which generates majority of the revenue, and product sales.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).